2-Hour Dispensing Evaluation of Samfilcon A Lenses With EPG01 Packaging Solution Compared to Commercially Available B+L Ultra Lenses
Phase: NA
Conditions: Contact Lens Wearer
Sponsor: Bausch & Lomb Incorporated

Jill Schafer

Protocol 21-003:  2-Hour Dispensing Evaluation of samfilcon A Lenses with EPG01 Packaging Solution 
Compared to Commercially Available B+L Ultra Lenses 
 
Version 1.0                                                              CONFIDENTIAL                   
August 13, 2021 
 
 
 
 
Page 3 of 49 
 
SYNOPSIS 
 
Name of Sponsor/Company: Bausch + Lomb Incorporated 
Name of Investigational Product: 
Test Lenses: samfilcon A with EPG01 Packaging Solution 
Control Lenses: Commercially available B+L Ultra Lenses 
Title of Study: 2-Hour Dispensing Evaluation of samfilcon A Lenses with EPG01 
Packaging Solution Compared to Commercially Available B+L Ultra Lenses 
Number of Clinical Centers: One Investigational Site- Bausch + Lomb Incorporated 
Primary Objective: The objective of this 2 hour study is to evaluate the clinical 
performance of samfilcon A lenses with an alternate packaging solution (EPG01) 
compared to commercially available B+L Ultra lenses.  
Methodology: Approximately 30 habitual soft contact lens wearing subjects will be 
enrolled in this two-hour randomized, contralateral, double-masked (subject and 
investigator masked), repeated measures dispensing study. All subjects will be seen 
for a Screening/Dispensing Visit at which informed consent will be obtained and 
eligibility will be assessed. If subjects satisfy all eligibility criteria and none of the 
exclusion criteria, subjects will be dispensed study lenses according to unique 
randomization schedules that will be provided to each Investigator. 
Number of Subjects Planned: Approximately 30 habitual soft contact lens wearing 
subjects will be enrolled. 
Diagnosis and Main Criteria for Inclusion: 
To be eligible for entry into the study, the subject must:  
1. Be 18 years or older on the date the Informed Consent Form (ICF) is signed and 
have capacity to read, understand and provide written voluntary informed 
consent.   
2. Have physiologically normal anterior segments not exhibiting clinically 
significant biomicroscopy findings.  
3. Have no active ocular disease or allergic conjunctivitis.  
4. Not be using any topical ocular medications.  
5. Be willing and able to follow instructions.  
6. Have signed a statement of informed consent. 
Key Exclusion Criteria: 
The subject is not eligible to participate in the study if the subject is:  
1. Participating in a conflicting study in the opinion of the Investigator.  
2. Considered by the Investigator to not be a suitable candidate for participation.  
Investigational Product, Dosage and Mode of Administration: The Investigator and 
subjects will be masked to the study lenses. Unmasked study personnel will be 
responsible for dispensing and collecting the study materials and accountability. The 
randomization schedule will be created prior to the start of the study by an unmasked 
statistician not otherwise involved in the study. Subjects will be receiving each of the 
study lens types once, in a randomized order. The subject will wear the study contact 
lenses for approximately 2 hours (Test lens in one eye and Control lens in the other 
eye). 

Protocol 21-003:  2-Hour Dispensing Evaluation of samfilcon A Lenses with EPG01 Packaging Solution 
Compared to Commercially Available B+L Ultra Lenses 
 
Version 1.0                                                              CONFIDENTIAL                   
August 13, 2021 
 
 
 
 
Page 4 of 49 
 
Study Duration of Treatment: Each subject will receive a study pair of lenses that 
will be worn for approximately 2 hours. Visit 1 will take approximately 20 minutes 
and Visit 2 will take approximately 15 minutes. Both visits will be on the same day. 
The clinical investigation will take approximately 2 weeks to complete. 
Schedule of Visits: 
Visit 1, Insertion 
 Subjects will have at least an 8 hour no lens washout period prior to their insertion visit. 
 Limbal and bulbar redness, corneal and conjunctival staining will be assessed with the 
slit lamp. 
 Percent area staining covered will be assessed for all 5 quadrants of the cornea. 
 A baseline spherical refraction will be performed, through which High Contrast/High 
Illumination (HCHI) logMAR visual acuity will be measured at 6m. 
 Each subject will insert a randomized lens pair.  
 Evaluate: sting/burn, dryness, comfort after 3 minutes of lens wear, centration, 
movement, wettability, deposits and preference based on comfort. 
 Spherical over-refraction will be performed through which HCHI logMAR visual acuity 
will be measured at 6m. 
 The subject will be instructed to wear the lens pair for approximately 2 hours.  
Visit 2 (After 2 Hours of Lens Wear) 
 Spherical over-refraction will be performed through which HCHI logMAR visual acuity 
will be measured at 6m. 
 Evaluate: sting/burn, dryness, comfort, preference for comfort, centration, movement, 
wettability and deposits and preference based on comfort.  
 Limbal and bulbar redness will be re-assessed.  
 Lenses will be collected and stored dry in a standard case.   
 Corneal and conjunctival staining will be re-assessed with the slit lamp. 
 Percent area staining covered will be assessed for all 5 quadrants of the cornea.   
 Digital photos of the cornea, conjunctiva, and lenses in situ may be acquired. 
 
Grading scales for the biomicroscopic evaluations and subject assessments are according 
to applicable Research Clinic procedures. See Appendix A: Methods of Clinical 
Evaluation. 
Study Endpoints:  
The primary endpoint is: 
1. Normalized logMAR Visual Acuity 
Statistical Methods: Continuous data will be summarized using descriptive statistics: 
n, mean, standard deviation, median, minimum and maximum. Categorical data will be 
presented by the total counts for each category and corresponding percentages. The data 
for each of the ordinal dependent measures (i.e., those assigned a clinical grade) will be 
analyzed using appropriate nonparametric techniques. Unless otherwise noted, paired t 
tests will be used to test for differences in means for each of the parametric dependent 
variables. Differences at the p < 0.05 level are considered to be statistically significant. 

Protocol 21-003:  2-Hour Dispensing Evaluation of samfilcon A Lenses with EPG01 Packaging Solution 
Compared to Commercially Available B+L Ultra Lenses 
 
Version 1.0                                                              CONFIDENTIAL                   
August 13, 2021 
 
 
 
 
Page 5 of 49 
 
Sample Size Calculations: In a previous study with similar lenses (ROC2-16-032), the 
standard deviation for logMAR VA was 0.069. A sample size of 15 subjects was 
calculated to have a study power of 80%. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Protocol 21-003:  2-Hour Dispensing Evaluation of samfilcon A Lenses with EPG01 Packaging Solution 
Compared to Commercially Available B+L Ultra Lenses 
 
Version 1.0                                                              CONFIDENTIAL                   
August 13, 2021 
 
 
 
 
Page 6 of 49 
 
Table of Contents 
INVESTIGATIONAL SITE AND STUDY PERSONNEL ................................................... 2 
SYNOPSIS .............................................................................................................................. 3 
1.0 INTRODUCTION .......................................................................................................... 10 
2.0 OBJECTIVE ................................................................................................................... 10 
3.0 STUDY DESIGN............................................................................................................ 10 
3.1 Description of Study Design ....................................................................................... 10 
3.2 Selection of Study Population ..................................................................................... 10 
3.2.1 Eligibility ............................................................................................................. 11 
3.2.1.1 Inclusion Criteria ........................................................................................... 11 
3.2.1.2 Exclusion Criteria .......................................................................................... 11 
3.2.2 Point of Enrollment and Randomization .............................................................. 11 
3.2.3 Subject Completion .............................................................................................. 11 
3.2.4 Lost to Follow-up ................................................................................................. 12 
3.3 Investigators ................................................................................................................ 12 
3.4 Study Duration ............................................................................................................ 12 
3.5 Protocol Changes and Amendments ........................................................................... 12 
4.0 STUDY MATERIALS ................................................................................................... 13 
4.1 Description of the Test Article(s) (Study Lenses) ...................................................... 13 
4.2 Description of Comparator Product(s) (Control Lenses) ............................................ 13 
4.3 Instructions for Use and Administration ..................................................................... 13 
4.3.1 Storage Requirements .......................................................................................... 13 
4.3.2 Subject Instructions .............................................................................................. 13 
4.4 Other Study Materials ................................................................................................. 14 
4.5 Packaging and Labeling .............................................................................................. 14 
4.6 Accountability ............................................................................................................. 14 
4.7 Masking....................................................................................................................... 14 
4.8 Product Replacement .................................................................................................. 14 
4.9 Risk Assessment ......................................................................................................... 14 
4.9.1 Risk Related to Subject ........................................................................................ 15 
4.9.2 Risk Related to Data Management ...................................................................... 15 
4.10 Relevance of Clinical Investigation .......................................................................... 15 
5.0 STUDY METHODS ....................................................................................................... 16 
5.1 Study Visits ................................................................................................................. 16 

Protocol 21-003:  2-Hour Dispensing Evaluation of samfilcon A Lenses with EPG01 Packaging Solution 
Compared to Commercially Available B+L Ultra Lenses 
 
Version 1.0                                                              CONFIDENTIAL                   
August 13, 2021 
 
 
 
 
Page 7 of 49 
 
5.1.1 METHODOLOGY: .............................................................................................. 16 
5.1.2 Unscheduled Visits .............................................................................................. 17 
5.1.3 Missed Visits ........................................................................................................ 17 
5.1.4 Post-Study Follow-up Visit ................................................................................. 17 
5.2 Study Completion ....................................................................................................... 17 
5.2.1 Study Termination/Suspension ............................................................................ 17 
5.2.2 Study Termination Procedure .............................................................................. 18 
5.3 Concomitant Medications/Therapy ............................................................................. 18 
5.4 Protocol Deviations ..................................................................................................... 18 
6.0 ADVERSE EVENTS (AE) ............................................................................................. 18 
6.1 Adverse Event Definitions .......................................................................................... 18 
6.1.1 Adverse Event (AE) ............................................................................................. 18 
6.1.2 Serious Adverse Event (SAE) .............................................................................. 19 
6.1.3 Serious Adverse Ocular Event ............................................................................. 19 
6.1.4 Significant, Non-Serious Adverse Event ............................................................. 20 
6.1.5 Non-significant, Non-serious Adverse Event ...................................................... 20 
6.1.6 Adverse Device Effect (ADE) ............................................................................. 20 
6.1.6.1 Anticipated Serious Adverse Device Effect (ASADE) ................................. 20 
6.1.6.2 Unanticipated Serious Adverse Device Effect (USADE) .............................. 21 
6.1.7 Device Deficiency ................................................................................................ 21 
6.2 Adverse Event Treatment and Culturing .................................................................... 21 
6.3 Adverse Event Identification and Evaluation ............................................................. 21 
6.4 Adverse Event Collection and Reporting ................................................................... 23 
6.5 Reporting Device Deficiencies ................................................................................... 24 
6.6 Emergency Contact Details for Reporting SAE and ADE ......................................... 24 
7.0 STATISTICAL METHODS ........................................................................................... 25 
7.1 Study Endpoints .......................................................................................................... 25 
7.2 Hypotheses .................................................................................................................. 25 
7.3 Sample Size ................................................................................................................. 25 
7.4 Randomization ............................................................................................................ 25 
7.5 Study Populations ....................................................................................................... 25 
7.6 Statistical Analysis ...................................................................................................... 25 
7.6.1 Pass/Fail Criteria .................................................................................................. 26 

Protocol 21-003:  2-Hour Dispensing Evaluation of samfilcon A Lenses with EPG01 Packaging Solution 
Compared to Commercially Available B+L Ultra Lenses 
 
Version 1.0                                                              CONFIDENTIAL                   
August 13, 2021 
 
 
 
 
Page 8 of 49 
 
7.6.2 Interim Analyses .................................................................................................. 26 
7.6.3 Exploratory/Sensitivity Analysis ......................................................................... 26 
7.6.4 Deviations ............................................................................................................ 26 
8.0 DATA QUALITY ASSURANCE .................................................................................. 26 
8.1 Study Monitoring ........................................................................................................ 26 
8.1.1 Monitoring Subject Risk ...................................................................................... 26 
8.1.2 Monitoring Informed Consent Process ................................................................ 26 
8.1.3 Data Verification .................................................................................................. 26 
8.1.3.1 Direct Entry with Verification ....................................................................... 27 
8.1.3.2 Double Entry of Data ..................................................................................... 27 
8.1.3.3 The Data Management Summary (DMS) ...................................................... 28 
8.1.4 Annual Research Clinic Monitoring Plan ............................................................ 28 
8.1.4.1 Monitoring Procedure .................................................................................... 28 
8.1.4.2 Site Performance Evaluation & Monitoring Report ...................................... 28 
8.2 Auditing Procedures.................................................................................................... 29 
8.3 Source Documentation ................................................................................................ 29 
8.4 Maintaining Subject Privacy ....................................................................................... 29 
8.5 Locking the Database .................................................................................................. 30 
8.6 Retention of Documents ............................................................................................. 30 
8.7 Clinical Quality Assurance ......................................................................................... 30 
8.8 Institutional Review Board ......................................................................................... 30 
8.9 Statements of Compliance .......................................................................................... 31 
8.10 Informed Consent Process ........................................................................................ 31 
8.10.1 Vulnerable Population ....................................................................................... 31 
8.11 Publication of Results ............................................................................................... 32 
9.0 BIBLIOGRAPHY ........................................................................................................... 32 
APPENDIX A: METHODS OF CLINICAL EVALUATION ............................................. 33 
APPENDIX B: SUBJECT INSTRUCTIONS FOR USE ..................................................... 42 
 

Protocol 21-003:  2-Hour Dispensing Evaluation of samfilcon A Lenses with EPG01 Packaging Solution 
Compared to Commercially Available B+L Ultra Lenses 
 
Version 1.0                                                              CONFIDENTIAL                   
August 13, 2021 
 
 
 
 
Page 9 of 49 
 
LIST OF ABBREVIATIONS 
 
Abbreviation/Acronym 
Term 
AE 
Adverse Event 
B+L 
Bausch + Lomb 
BSCVA 
Best Spectacle-Corrected Visual Acuity 
CFR 
Code of Federal Regulations 
CRT 
Clinical Research Technician  
CRF/e-CRF 
Case Report Form / Electronic Case Report Form 
D 
Diopter 
DOB 
Date of Birth 
EDC 
Electronic Data Capture 
EC 
Ethics Committee 
FDA 
United States Food and Drug Administration 
GCPs 
Good Clinical Practices 
GPRM 
Global Pharmacovigilance and Risk Management 
GPS 
Global Product Surveillance 
GSSP 
Global Safety Surveillance and Pharmacovigilance 
HIPAA 
Health Insurance Portability and Accountability Act 
ICF 
Informed Consent Form 
ID 
Identification 
IRB 
Institutional Review Board 
ISO 
International Organization for Standardization 
logMAR 
Logarithm of the Minimum Angle of Resolution 
PVVAT 
Visual Acuity Software from Precision Vision 
US 
United States 
USC 
United States Code 
VA 
Visual Acuity 
NOTE:  The first occurrence of some abbreviations is not spelled out in the document (e.g., units of 
measure). 
 
 
 

Protocol 21-003:  2-Hour Dispensing Evaluation of samfilcon A Lenses with EPG01 Packaging Solution 
Compared to Commercially Available B+L Ultra Lenses 
 
Version 1.0                                                              CONFIDENTIAL                   
August 13, 2021 
 
 
 
 
Page 10 of 49 
 
1.0 INTRODUCTION 
The EU Medical Device Regulation (Regulation (EU) 2017/745) has identified ‘Boric Acid 
or Borate components’ as ‘Restricted Substances’ as they have been labelled as substances 
of very high concern (SVHC). This means that sodium borate and boric acid will need to be 
either listed with a potential warning or replaced in B+L’s packaging solutions. B+L has 
deemed it necessary to develop an alternative packaging solution by replacing the current 
borate-based packaging solutions with a phosphate-based packaging solution. This clinical 
study is will evaluate the clinical performance of Bausch + Lomb ULTRA (samfilcon A) 
Visibility Tinted Soft Contact Lenses with an alternate packaging solution (EPG01) 
compared to commercially available Bausch+ Lomb ULTRA (samfilcon A) contact lenses. 
This contact lens packaging solution contains known elements in the ophthalmic industry 
and is safe for use. 
 
2.0 OBJECTIVE 
The objective of this two hour study is to evaluate the clinical performance of samfilcon A 
lenses with an alternate packaging solution (EPG01) compared to commercially available 
B+L Ultra Lenses. This novel contact lens packaging solution contains known elements in 
the ophthalmic industry and is safe for use. 
 
3.0 STUDY DESIGN 
 
3.1 Description of Study Design 
Approximately 30 habitual soft contact lens wearing subjects will be enrolled in this two-
hour randomized, contralateral, double-masked (subject and investigator masked), repeated 
measures dispensing study. All subjects will be seen for a Screening/Dispensing Visit at 
which informed consent will be obtained and eligibility will be assessed. If subjects satisfy 
all eligibility criteria and none of the exclusion criteria, subjects will be dispensed study 
lenses according to unique randomization schedules that will be provided to each 
Investigator. 
 
There are two study lenses (one test and one control). Each subject will receive a pair of 
study contact lenses that will be worn for approximately 2 hours (test lens in one eye and 
control lens in the other eye). Subjects will complete a minimum of 1 study visit and a 
maximum of 2 study visits.  
 
Visit 1: Approximately 20 minutes 
Visit 2: Approximately 15 minutes 
Both study visits will occur on the same day.  
 
The clinical investigation will take approximately 2 weeks to complete. 
 
3.2 Selection of Study Population 
Written informed consent, enrollment in the study, or dispensing of study products 
cannot begin until the Investigator has received Institutional Review Board (IRB)/Ethics 
Committee (EC) approval to conduct the study. 

Protocol 21-003:  2-Hour Dispensing Evaluation of samfilcon A Lenses with EPG01 Packaging Solution 
Compared to Commercially Available B+L Ultra Lenses 
 
Version 1.0                                                              CONFIDENTIAL                   
August 13, 2021 
 
 
 
 
Page 11 of 49 
 
Recruitment for this study will target habitual soft contact lens wearers who have an 
Rx suitable for the available lens powers will be enrolled in this dispensing study. 
 
To reduce the foreseeable factors that could compromise the outcome of the clinical 
investigation, subjects are targeted who are habitual contact lens wearers. To be eligible to 
participate, subjects must have physiologically normal anterior segments not exhibiting 
clinically significant biomicroscopy findings, no active ocular disease or allergic 
conjunctivitis, not using any topical ocular medications and be willing and able to follow 
instructions.  
 
3.2.1 Eligibility 
3.2.1.1 Inclusion Criteria 
To be eligible for entry into the study, the subject must:  
1. Be 18 years or older on the date the Informed Consent Form (ICF) is signed and 
have capacity to read, understand and provide written voluntary informed consent.  
2. Have physiologically normal anterior segments not exhibiting clinically 
significant biomicroscopy findings.  
3. Have no active ocular disease or allergic conjunctivitis.  
4. Not be using any topical ocular medications.  
5. Be willing and able to follow instructions.  
6. Have signed a statement of informed consent.  
 
3.2.1.2 Exclusion Criteria 
The subject is not eligible to participate in the study if the subject is:  
1. Participating in a conflicting study in the opinion of the Investigator.  
2. Considered by the Investigator to not be a suitable candidate for participation.  
 
3.2.2 Point of Enrollment and Randomization 
Both the study subject and investigator will be masked. An unmasked designee will be 
responsible for dispensing study products to the subjects according to the randomization 
schedule. The randomization schedule will be produced prior to study enrollment by Bausch 
+ Lomb’s unmasked statistician not otherwise involved in the study. 
 
Randomization will be completed by the unmasked designee. The subjects will be assigned 
randomization numbers sequentially as they are enrolled. The unmasked designee is 
responsible for preparing the clinical trial materials according to the randomization 
schedule. The unmasked designee is also responsible for maintaining study lens inventory, 
randomization schedule and the Product Accountability Log in a masked fashion. 
 
3.2.3 Subject Completion 
The subject will have completed the study when he/she has worn the study lenses for 
approximately 2 hours. Subjects who require further follow-up due to an ongoing Adverse 
Event will be followed according to the Adverse Event Section 6.0. 
 

Protocol 21-003:  2-Hour Dispensing Evaluation of samfilcon A Lenses with EPG01 Packaging Solution 
Compared to Commercially Available B+L Ultra Lenses 
 
Version 1.0                                                              CONFIDENTIAL                   
August 13, 2021 
 
 
 
 
Page 12 of 49 
 
The Investigator may discontinue a subject during the study for any reason if, in his or her 
opinion, it is in the best interest of the subject. Reasons for discontinuation include but are 
not limited to:  
• 
adverse effects  
• 
other ocular complications  
• 
subject non-compliance  
• 
subject request  
• 
subject found to be ineligible during study participation*  
*Any subject enrolled in the study, who later is found to have not met any of the eligibility 
criteria at entry, will be discontinued at the Sponsor’s request.  
  
Subject discontinuations will be documented clearly on the applicable case report form.   
Subjects that are discontinued from the study following randomization will not be replaced.  
 
Exit visits should be completed for early terminated subjects. 
 
The completion of the clinical investigation shall be deemed to coincide with the last visit 
of the last subject and when follow-up is complete. 
 
3.2.4 Lost to Follow-up 
Subjects who do not return for scheduled follow-up visits, as defined by the visit window 
and cannot be contacted, are to be considered lost to follow-up. All attempts to contact the 
subject should be documented and kept with the subject’s source documentation, and the 
applicable CRF/eCRFs will be completed.  
 
3.3 Investigators 
The study will be conducted at one investigative site, the Bausch + Lomb Research Clinic in 
Rochester, NY by Investigators who are employed by Bausch + Lomb. The Investigators 
are qualified by training and experience to conduct this study. All the study procedures will 
be performed by Optometrists who are licensed to fit contact lenses. 
 
The assessments required for the study are routinely performed by Optometrists and are 
standard of care for contact lens wearers. (See Appendix A: Methods of Clinical Evaluation 
for detailed information about study procedures).  
 
3.4 Study Duration 
The clinical investigation will take approximately 2 weeks to complete. 
 
3.5 Protocol Changes and Amendments 
Changes to the protocol will be approved by the Sponsor. An amendment to the protocol 
may also require submission and approval from the IRB before implementation. The 
Investigator is responsible for the ensuring that staff involved have completed training on 
the changes before implementing with subjects. 
 
 

Protocol 21-003:  2-Hour Dispensing Evaluation of samfilcon A Lenses with EPG01 Packaging Solution 
Compared to Commercially Available B+L Ultra Lenses 
 
Version 1.0                                                              CONFIDENTIAL                   
August 13, 2021 
 
 
 
 
Page 13 of 49 
 
4.0 STUDY MATERIALS 
Bausch + Lomb will provide all study materials. Subjects must use only study supplied 
contact lenses during the study.  Use of other prescribed contact lenses and solution is not 
permitted during the study (both visits will occur on the same day). 
 
4.1 Description of the Test Article(s) (Study Lenses) 
Test: samfilcon A lenses with Alternate Packaging Solution EPG01 (T01: sam A EPG01) 
 
The Bausch + Lomb ULTRA (samfilcon A) Contact Lens material is a hydrophilic 
copolymer of a siloxane methacrylate and N-vinyl pyrrolidone, and is 46% water by weight 
when immersed in a phosphate buffered solution. This lens is tinted with up to 200 ppm of 
Reactive Dye 246. The monomer, samifilcon A, is cast molded using established Bausch + 
Lomb lens making techniques. 
 
4.2 Description of Comparator Product(s) (Control Lenses) 
Control: Commercially available B+L Ultra lenses (C01: Ultra) 
 
The Commercially available Bausch + Lomb Ultra lens is supplied in a polypropylene 
blister that contains a borate-based packaging solution. 
 
4.3 Instructions for Use and Administration 
The Investigator and subjects will be masked to the study lenses. Unmasked study personnel 
will be responsible for dispensing and collecting the study materials and accountability. The 
randomization schedule will be created prior to the start of the study by an unmasked 
statistician not otherwise involved in the study.  
 
Subjects will be receiving each of the study lens types once, in a randomized order. The 
subject will wear the study contact lenses for approximately 2 hours (Test lens in one eye 
and Control lens in the other eye). See Appendix B for additional Instructions for Use. 
 
4.3.1 Storage Requirements 
All study materials provided by the Sponsor must be stored in a secure location 
accessible only to unmasked study personnel. 
 
4.3.2 Subject Instructions 
a) Subject Instructions for the use of study lenses are included in Appendix B, which 
include precautions and warnings related to contact lens wear and contact lens solution. 
Subjects must comply with the instructions provided to them.  
 
b) The Investigator or other designee must review, with the subject, the Subject 
Instructions and the precautions and warnings, as appropriate for the study. 
 
c) Any subject who does not follow instructions to a degree that, in the Sponsor or 
Investigator's opinion, jeopardizes the subject's well-being or the validity of the study, 
should be discontinued. 

Protocol 21-003:  2-Hour Dispensing Evaluation of samfilcon A Lenses with EPG01 Packaging Solution 
Compared to Commercially Available B+L Ultra Lenses 
 
Version 1.0                                                              CONFIDENTIAL                   
August 13, 2021 
 
 
 
 
Page 14 of 49 
 
4.4 Other Study Materials 
Used and unused study materials will be returned after the study is complete. No other study 
materials will be used in this study. 
 
4.5 Packaging and Labeling 
The test contact lens will be packaged with an investigational label. Bausch + Lomb 
ULTRA (samfilcon A) Contact Lens is supplied in a polypropylene blister that contains a 
phosphate buffered saline solution. The contact lens packaging solution contains known 
elements in the ophthalmic industry and is safe for use. The blisters are sealed with a 
plastic-coated aluminum foil lid stock, with each blister labeled with the manufacturing lot 
number of the lens, diameter, sphere power, base curve, and expiration date. 
 
The Control contact lenses will be packaged with a Commercial label.  
The label will contain the following information at minimum: 
• lot number 
• manufacturer’s name 
• manufacturer’s place of business 
• expiration date 
 
4.6 Accountability 
The investigational site is responsible for keeping current and accurate records of the 
amount of study materials received and dispensed, and its disposition. The study lenses 
must be stored under the appropriate conditions in a secure area and are to be dispensed 
only to subjects enrolled in the study, in accordance with the conditions specified in this 
protocol.  
 
All test materials will be accounted for on the Clinical Trial Materials Form and 
Lens/Solution Tracking Form. Subjects must return all remaining study materials to the 
Investigator at the final study visit, or their exit visit if discontinued prior to this visit. 
 
4.7 Masking 
The Investigator and subjects will be masked to the study lenses. Unmasked study personnel 
will be responsible for dispensing and collecting CTM Material and accountability. 
 
The randomization schedule will be created prior to the start of the study by an unmasked 
statistician not otherwise involved in the study.  
 
4.8 Product Replacement 
Not applicable. Since it is a 2 Hour study, there is no foreseen need for product replacement 
during the study. 
 
4.9 Risk Assessment 
Information concerning potential risks associated with the investigational device (as well as 
possible interactions with concomitant medical treatments and risk-to-benefit ratio) can be 
found within the Investigator’s Brochure. Risks are also summarized within the Informed 

Protocol 21-003:  2-Hour Dispensing Evaluation of samfilcon A Lenses with EPG01 Packaging Solution 
Compared to Commercially Available B+L Ultra Lenses 
 
Version 1.0                                                              CONFIDENTIAL                   
August 13, 2021 
 
 
 
 
Page 15 of 49 
 
Consent Form (ICF)document. The assessments required for the study are routinely 
performed and are standard of care for contact lens wearers. The subjects will be informed 
of any potential study specific risks in the ICF or if new risks become apparent during the 
study. 
 
4.9.1 Risk Related to Subject 
 
With contact lens wear there may be increased risk of corneal edema (swelling of the 
cornea) which may temporarily affect vision or comfort, neovascularization (small blood 
vessels growing into the cornea), giant papillary conjunctivitis (small bumps on the inside 
of the eyelids), iritis (internal inflammation in the eye), corneal infiltrates (corneal 
inflammation) and corneal erosion/abrasion or corneal infection, which if untreated may 
cause ocular problems. 
 
The risks involved in this study will be minimized because the subjects will be examined 
frequently and at specified intervals.  The risks are further minimized by the study 
eligibility criteria.  
 
B+L Ultra contact lenses are commercially available in the United States. 
 
The subject may not personally benefit from being in this study other than getting the 
opportunity to wear different types of contact lenses.  However, study results may allow a 
new or improved product to be marketed in the future giving benefit to other contact lens 
users. 
4.9.2 Risk Related to Data Management 
The risks involved in this study related to data management will be minimized because the 
Clinical Research Technician (CRT) will enter the data directly into the Electronic Data 
Capture (EDC) system. The Primary Investigator or Delegate will visually verify the data as 
it is entered, except masked information when applicable.  If data is not entered directly into 
the EDC System, the data will be double entered.  Then, the two sets of data will be 
compared to each other and then checked for discrepancies.  
  
Risk of data management is further minimized by edit checks built into the EDC system to 
minimize the chance of error.  For example, the EDC system does not allow the same study 
material (solution or lens) to be dispensed more than once. Also, the expected ranges of 
values are specified in the EDC system. If data falls outside of the expected range, the CRT 
will be prompted to answer a query. 
 
4.10 Relevance of Clinical Investigation 
B+ L has deemed it necessary to develop an alternative packaging solution by replacing 
the current borate-based packaging solutions with a phosphate-based packaging solution. 
A clinical study is required to evaluate the clinical performance of Bausch + Lomb 
ULTRA (samfilcon A) Visibility Tinted Soft Contact Lenses with an alternate packaging 
solution (EPG01) compared to commercially available Bausch+ Lomb ULTRA (samfilcon 
A) contact lenses. This contact lens packaging solution contains known elements in the 
ophthalmic industry and is safe for use. 

Protocol 21-003:  2-Hour Dispensing Evaluation of samfilcon A Lenses with EPG01 Packaging Solution 
Compared to Commercially Available B+L Ultra Lenses 
 
Version 1.0                                                              CONFIDENTIAL                   
August 13, 2021 
 
 
 
 
Page 16 of 49 
 
Further information regarding the relevance of this study in the context of state of the art 
clinical practice such as background information, summary of relevant literature, 
mechanism of action, intended clinical performance, and a summary of existing relevant 
clinical data of the investigational device can be found in the Investigator’s Brochure. 
 
5.0 STUDY METHODS 
The clinical procedures in this study are part of normal eye examination. There are not any 
deviations from normal clinical practice. The procedures conducted in the study are outlined 
below and described in Appendix A: Methods of Clinical Evaluation. 
 
Following identification of a potential subject, the Investigator (or designee) will explain 
the purpose of the study, procedures, risks/benefits, and subject responsibilities to the 
potential subject. The subject’s willingness and ability to meet the follow-up requirements 
of the study will be determined. If the subject chooses to participate in the investigation, 
written informed consent will be obtained. The subject and the person obtaining written 
consent will sign and date the IRB-approved ICF. The Investigator must keep the signed ICF 
document. The signed original document should be retained in the subject’s records, and a 
copy should be provided to the subject. In addition, the applicable privacy regulation 
requirements must be met. Additional Informed Consent information is provided in Section 
8.10. 
 
5.1 Study Visits 
5.1.1 METHODOLOGY: 
Visit 1, Insertion 
 Subjects will have at least an 8 hour no lens washout period prior to their insertion visit. 
 Limbal and bulbar redness, corneal and conjunctival staining will be assessed with the slit 
lamp. 
 Percent area staining covered will be assessed for all 5 quadrants of the cornea. 
 A baseline spherical refraction will be performed, through which High Contrast/High 
Illumination (HCHI) logMAR visual acuity will be measured at 6m. 
 Each subject will insert a randomized lens pair.  
 Evaluate: sting/burn, dryness, comfort after 3 minutes of lens wear, centration, movement, 
wettability, deposits and preference based on comfort. 
 Spherical over-refraction will be performed through which HCHI logMAR visual acuity 
will be measured at 6m. 
 The subject will be instructed to wear the lens pair for approximately 2 hours.  
 
Visit 2, Follow-up After 2 Hours of Lens Wear 
 Spherical over-refraction will be performed through which HCHI logMAR visual acuity 
will be measured at 6m. 
 Evaluate: sting/burn, dryness, comfort, preference for comfort, centration, movement, 
wettability, deposits and preference based on comfort.  
 Limbal and bulbar redness will be re-assessed.  
 Lenses will be harvested, stored dry in a standard case.   
 Corneal and conjunctival staining will be re-assessed with the slit lamp. 

Protocol 21-003:  2-Hour Dispensing Evaluation of samfilcon A Lenses with EPG01 Packaging Solution 
Compared to Commercially Available B+L Ultra Lenses 
 
Version 1.0                                                              CONFIDENTIAL                   
August 13, 2021 
 
 
 
 
Page 17 of 49 
 
 Percent area staining covered will be assessed for all 5 quadrants of the cornea.   
 Digital photos of the cornea, conjunctiva, and lenses in situ may be acquired. 
 
Grading scales for the biomicroscopic evaluations and subject assessments are according to 
applicable Research Clinic procedures. See Appendix A: Methods of Clinical Evaluation. 
 
5.1.2 Unscheduled Visits 
Additional visits may be scheduled, as necessary, to ensure the safety and well-being of 
subjects. All additional exams should be fully documented on Unscheduled Visit forms as 
appropriate.  
 
5.1.3 Missed Visits 
If a subject misses a Study Visit, the visit is considered missed and the subject must be 
exited from the study. The Investigator or designee must check the missed visit box on the 
first page of the applicable CRF/e-CRF for that visit. 
 
See Section 3.2.4 Lost to Follow-Up for applicable instructions for subjects who do not 
return for the final visit. 
 
5.1.4 Post-Study Follow-up Visit 
There is no planned follow-up period after the clinical investigation is complete. If a subject 
requires further follow-up upon discontinuation or completion of the study, the 
Investigator must schedule post-study follow-up visits, as necessary. The Investigator is 
required to follow the subject until the condition no longer warrants further follow-up for 
study purposes. A Post-Study Follow-up Visit e-CRF/CRF must be completed for each of 
these visits. 
 
There will not be any routine eye care provided after the clinical investigation is complete. 
Subjects should follow-up with their eye care provider every 1-2 years for comprehensive 
eye care or sooner as recommended by their eye care provider.   
 
5.2 Study Completion 
The subject has completed the study when the second visit is concluded. Subjects who 
require further follow-up will be followed according to the Adverse Event or Post- Study 
Follow-Up Section. There is no planned follow-up period after the clinical investigation is 
complete. 
 
The completion of the clinical investigation shall be deemed to coincide with the last visit 
of the last subject and when follow-up is complete. 
 
5.2.1 Study Termination/Suspension  
If during the study it becomes evident that the study should be stopped prematurely or 
placed on hold, appropriate notification will be given to the requestor and IRB/ECs, as 
applicable. Should the Investigator and/or study requester wish to terminate the study, the 
following Research Clinic procedure will be followed. Any subjects with ongoing Adverse 

Protocol 21-003:  2-Hour Dispensing Evaluation of samfilcon A Lenses with EPG01 Packaging Solution 
Compared to Commercially Available B+L Ultra Lenses 
 
Version 1.0                                                              CONFIDENTIAL                   
August 13, 2021 
 
 
 
 
Page 18 of 49 
 
Events at the time of premature study termination or hold will be followed by the 
Investigator. 
  
5.2.2 Study Termination Procedure 
The decision to terminate a study will be made by the Director of Clinical Affairs and the 
Principal Investigator (PI). A final slit lamp examination should be performed, and adverse 
events handled accordingly. All investigational materials (lenses, solutions, and / or 
devices) will be retrieved, all subjects will be exited, and the Trial Master File will be 
reconciled.  A clinical report will be written and include the reason for study termination.   
 
5.3 Concomitant Medications/Therapy 
Ocular, systemic or topical medications that, in the Investigator’s opinion, 
could potentially affect ocular physiology or lens/solution performance are prohibited. 
 
5.4 Protocol Deviations 
The date of and reason for deviations will be documented in all cases. Significant or 
major protocol deviations impacting the safety of the subject or the integrity of the study 
must be reported by the Investigator to the IRB immediately. Reporting of all other protocol 
deviations must adhere to the requirements of the governing IRB/EC.  
 
Any subject enrolled in the study who later is found to have not met the eligibility criteria 
at entry will be discontinued. Otherwise, unless the protocol deviations put the subject at 
risk or the subject’s condition requires that they be discontinued from the study, subjects 
may continue to participate until the end of the study. 
 
6.0 ADVERSE EVENTS (AE) 
Subjects who experience an adverse event during study participation will be discontinued 
from study participation, but will be followed by the Investigator until resolution of the 
adverse event or until the Investigator determines that further improvement is not expected.  
 
6.1 Adverse Event Definitions 
For the purposes of this study, reportable AEs include ocular AEs and non-ocular serious 
adverse events (SAEs). All AEs will be classified first for seriousness and significance and 
then as to whether or not they are device related or non-device related and if device related, 
then, if it is an adverse device effect (ADE), an anticipated serious adverse device effect 
(ASADEs) or an unanticipated serious adverse device effect (USADEs). AEs, ADEs, 
ASADEs, USADEs, SAEs, Significant Non-Serious AEs and Non-Significant Non- 
Serious AEs are defined as follows: 
 
6.1.1 Adverse Event (AE) 
Any untoward medical occurrence, unintended disease or injury, or untoward clinical signs 
(including abnormal laboratory findings) in subjects or users, whether or not related to the 
investigational medical device. Adverse events should be categorized as device related or 
non-device related.  
Throughout the course of this study all efforts will be made to remain alert to reportable 

Protocol 21-003:  2-Hour Dispensing Evaluation of samfilcon A Lenses with EPG01 Packaging Solution 
Compared to Commercially Available B+L Ultra Lenses 
 
Version 1.0                                                              CONFIDENTIAL                   
August 13, 2021 
 
 
 
 
Page 19 of 49 
 
AEs. If an AE occurs, the first concern will be the safety of the subject and appropriate 
medical intervention will be made. 
 
All reportable AEs occurring after signing of informed consent and through the subject’s 
end of participation in the study must be reported. All reportable AEs must be followed 
until the event resolves or stabilizes. 
 
6.1.2 Serious Adverse Event (SAE) 
An adverse event which:  
• Led to death; 
• Led to serious deterioration in the health of the subject, that resulted in: 
o A life-threatening illness or injury; or 
o A permanent impairment of a body structure or a body function (e.g., 
blindness); or  
o Inpatient or prolonged hospitalization; or 
o Medical or surgical intervention to prevent life-threatening illness or  
o Injury or permanent impairment to a body structure or a body function; 
• Led to fetal distress, fetal death, or a congenital abnormality or birth defect. 
6.1.3 Serious Adverse Ocular Event  
Serious Adverse Ocular Event is a serious adverse event that results in, or has potential to 
cause, either permanent impairment of an ocular function or damage to an ocular structure 
and may necessitate medical or surgical intervention. Serious Adverse Events require 
expedited reporting. Serious adverse events include any hazardous, sight-threatening 
conditions occurring after exposure to a test article, including but not limited to the 
following: 
 
• A presumed infectious ulcer (defined as a progressive erosion of the corneal tissue). 
For the purposes of reporting, a corneal ulcer which has any of the following 
characteristics should be considered in this category: 
o Central or paracentral location; 
o Penetration of Bowman’s membrane; 
o Infiltrate ≥2 mm diameter; 
o Associated with iritis;  
o Associated with any increase in intraocular pressure; 
o Culture positive for microorganisms; 
o Increasing size or severity at subsequent visits. 
 
Note: Signs of a presumed infectious ulcer may include irregular focal infiltrates; 
active lesions with raised edges; significant diffuse infiltration; anterior corneal to 
mid-stromal involvement; erosion with overlying staining; conjunctival and lid 
edema; anterior chamber reaction (iritis); severe bulbar and limbal redness. 
Symptoms associated with a presumed infectious ulcer (microbial keratitis) may 
include pain of rapid onset; severe redness; purulent or mucopurulent discharge; 
tearing; photophobia. 

Protocol 21-003:  2-Hour Dispensing Evaluation of samfilcon A Lenses with EPG01 Packaging Solution 
Compared to Commercially Available B+L Ultra Lenses 
 
Version 1.0                                                              CONFIDENTIAL                   
August 13, 2021 
 
 
 
 
Page 20 of 49 
 
 
• Any central or paracentral (within 6 mm of cornea) corneal event that results in 
permanent opacification (such as corneal scar or vascularization) 
• Any serious adverse ophthalmic events including hypopyon and hyphema. 
• Any neovascularization within the central 6 mm of the cornea. 
• Permanent loss of 2 or more lines (10 letters) of BSCVA. 
• All cases of iritis. 
 
6.1.4 Significant, Non-Serious Adverse Event  
A Significant, Non-Serious Adverse Event is an Adverse Event that does not meet the 
serious criteria, is considered significant, and requires expedited reporting. These events 
include (but are not limited to): 
• Peripheral non-progressive non-infectious corneal ulcer 
• All symptomatic corneal infiltrative events 
• All cases of corneal staining severity greater than or equal to Grade 3 
• A temporary loss of 2 or more lines (10 or more letters) of BSCVA (for greater than 
or equal to 2 weeks) 
• Increase in neovascularization of 1.5mm or greater. 
• Any ocular event that necessitates temporary lens discontinuation of greater than or 
equal to 2 weeks. 
 
6.1.5 Non-significant, Non-serious Adverse Event 
A Non-Significant Non-Serious Adverse Event may include (but are not limited to) and 
does not require expedited reporting: 
• Asymptomatic, peripheral, corneal infiltrative events. 
• Bacterial Conjunctivitis 
• Viral Conjunctivitis 
• Allergic Conjunctivitis 
• Corneal Edema 
• Contact Lens Related Papillary Conjunctivitis 
 
6.1.6 Adverse Device Effect (ADE) 
An ADE is an Adverse Event that is assessed to be related to the use of an investigational 
medical device. This definition includes Adverse Events resulting from insufficient or 
inadequate instructions for use; deployment, implantation, installation, or operation; or any 
malfunction of the investigational medical device. This definition also includes any event 
resulting from use error or from intentional misuse of the investigational medical device. 
 
6.1.6.1 Anticipated Serious Adverse Device Effect (ASADE)  
An ASADE is an ADE that first meets the serious criteria (see definition above for Serious 
Adverse Event) or significant, non-serious criteria (see above definition for significant, non-
serious AE) and which, by its nature, incidence, severity or outcome, has been previously 
identified in the investigational plan or application (including a supplementary plan or 
application) and/or in the risk analysis report. ASADEs include: 

Protocol 21-003:  2-Hour Dispensing Evaluation of samfilcon A Lenses with EPG01 Packaging Solution 
Compared to Commercially Available B+L Ultra Lenses 
 
Version 1.0                                                              CONFIDENTIAL                   
August 13, 2021 
 
 
 
 
Page 21 of 49 
 
• Corneal Ulcer (infectious or non-infectious) 
• Keratitis 
• Sensitivity to light (photophobia) 
• Excessive eye secretions including mucopurulent discharge 
• Blurred vision, rainbows or halos around objects 
• Poor visual acuity (reduced sharpness of vision) 
• Moderate to severe eye pain not relieved by removing the lens 
 
6.1.6.2 Unanticipated Serious Adverse Device Effect (USADE) 
An USADE is an ADE that first meets the serious criteria (see definition above for Serious 
Adverse Event) or significant, non-serious criteria (see above definition for significant, non-
serious AE) and has an effect on health or safety or any life-threatening problem or death 
caused by, or associated with, a device if that effect, problem or death was not previously 
identified in nature, severity or degree of incidence in the investigational plan or application 
(including a supplementary plan or application), or any other unanticipated serious problem 
associated with a device that relates to the rights, safety, or welfare of subjects. 
 
6.1.7 Device Deficiency 
Inadequacy of an investigational medical device with respect to its identity, quality, 
durability, reliability, safety, or performance. This includes malfunctions, use errors, 
inadequate labelling, insufficient or inadequate instructions for use. A Device Deficiency 
can occur with or without the occurrence of an Adverse Event. 
 
6.2 Adverse Event Treatment and Culturing 
With any Adverse Event, treat the subject as appropriate to prevent further complications 
and to potentially resolve the event consistent with the standard of care. 
 
A culture should be obtained in cases of corneal ulcer or suspected  ocular infection, unless 
medically contraindicated. Cultures should be taken from the cul-de-sac, lower eyelid 
margin, and the corneal lesion (if applicable). When a culture is obtained, the contact lenses 
and contact lens cases which were being utilized by the subject at the time of the AE should 
be collected from the subject (if available at the time of the  culture) for culturing and 
processing by the clinical laboratory designated by the Research Clinic. Microbial data 
generated from returned subject supplies (e.g., lenses, lens cases and/or lens case solutions) 
are for  information only. Because microbes may be introduced into subject supplies during 
use, recovery of microbes from returned subject supplies cannot be presumed to indicate 
etiology or direction of organism transmission. The ocular cultures, along with the 
associated contact lenses and contact lens cases, will be sent to the clinical laboratory 
designated by the Research Clinic for analysis. The clinical laboratory will report the 
culture results to both the Investigator and to the Research Clinic, the Investigator will 
record the results in the applicable form. 
 
6.3 Adverse Event Identification and Evaluation  
Throughout the course of a study all efforts will be made to remain alert to Adverse Events 

Protocol 21-003:  2-Hour Dispensing Evaluation of samfilcon A Lenses with EPG01 Packaging Solution 
Compared to Commercially Available B+L Ultra Lenses 
 
Version 1.0                                                              CONFIDENTIAL                   
August 13, 2021 
 
 
 
 
Page 22 of 49 
 
(AEs). If an AE occurs, the first concern will be the safety of the subject and appropriate 
medical intervention will be made. The associated product should be retained for further 
analysis, if needed. 
 
All AEs occurring after signing the informed consent and through the end of the subject’s 
participation in the study must be recorded and reported, if applicable. All AEs must be 
followed until the event resolves or stabilizes.  
 
Identify potential adverse events during a clinical study by using the following sources: 
• Direct observation by the Investigator 
• Asking the study participant using a non-specific question (i.e. Have you had any 
problems since the last visit?) 
• Unsolicited volunteering of information by the study participant (i.e. Doctor, I have 
had numerous headaches since I started using this lens) 
• Laboratory or test results that meet protocol requirements for classification as an 
adverse event (i.e. IOP over 30mmHg) 
• When evaluating AEs, the Investigator should classify the AE based on the 
following three criteria: 
1. Seriousness and/or significance (based on the criteria provided in Section 6.1)  
 
Severity: 
• Mild: Subject awareness of a sign or symptom that is easily tolerated, requires no 
treatment, and does not interfere with subject’s daily activities. 
 
• Moderate: Subject awareness of a sign or symptom which may be a low level of 
concern to the subject and may interfere with daily activities but can be relieved by 
simple therapeutic care. 
 
• Severe: A sign or symptom that interrupts the subject’s daily activity and requires 
systemic therapy or other treatment. 
 
2. The relationship of the event to the study device using the following guidelines:   
• Related: There is at least a reasonable possibility that the AE is related to the study 
device (contact lens) and/or solution or rewetting drops. Reasonable possibility 
means that there is evidence to suggest a causal relationship or association between 
the study device and/or solution or rewetting drops and the AE. Also referred to as 
an ADE.  
• Not Related: There is little or no reasonable possibility that the AE is related to the 
study device (contact lens) and/or solution or rewetting drops. This assessment 
implies that the AE has no evidence to suggest either a causal relationship or 
association to the study device and/or solution or rewetting drops and a more likely 
or certain alternative etiology exists. 
3. Expectedness of the event  
• Unexpected Adverse Event (UAE):  Unexpected Adverse Events must be reported 
to the IRB within 10 calendar days of discovery. 

Protocol 21-003:  2-Hour Dispensing Evaluation of samfilcon A Lenses with EPG01 Packaging Solution 
Compared to Commercially Available B+L Ultra Lenses 
 
Version 1.0                                                              CONFIDENTIAL                   
August 13, 2021 
 
 
 
 
Page 23 of 49 
 
• Expected Adverse Event: An adverse event of which, the nature or severity of which 
is consistent with the current product labeling, investigator brochure, data sheet, etc. 
 
6.4 Adverse Event Collection and Reporting 
The Research Clinic will delegate each function’s roles and responsibilities related to 
adverse event reporting. The Director of Clinical Affairs is responsible for ensuring that all 
Research Clinic Staff understand their responsibilities for collecting and assessing adverse 
event information and forwarding applicable adverse event information to the appropriate 
business function. 
 
Research Clinic Staff are responsible for understanding the procedures for adverse event 
collection, evaluation, documentation, and reporting. 
 
• Collect and record information about any identified adverse event (including the 
date of the adverse event, treatment, resolution, assessment of both the seriousness 
and the relationship to the investigational device and the related procedure) on the 
Adverse Event form. The Adverse Event Form will be completed each time the 
subject is seen during the management of the incident and at resolution of the 
incident.  
• If an adverse event is determined to be serious or significant and non-serious, notify 
the Principal Investigator immediately. 
• Report all serious or significant and non-serious adverse events within twenty-four 
(24) hours to Regulatory Affairs, Global Product Surveillance and/or Global Safety 
Surveillance and Pharmacovigilance as appropriate for the product being evaluated. 
Continue to send follow-up information or provide support to the appropriate 
reporting business function for any serious adverse event as soon as it becomes 
available. 
• Ensure that the subject’s identity is protected and the subject’s identifiers in the 
study are properly documented on the form.   
• Report all unexpected adverse device effects to the reviewing Institutional Review 
Board within 10 business days of discovery.  Continue to send follow-up 
information as soon as it becomes available. 
• Report any adverse event resulting from Intentional Misuse of an investigational 
medical device per the same procedures as above.  
• Report any adverse event resulting from a Device Deficiency per the same 
procedures as above. All Device Deficiencies should be recorded and evaluated for 
the potential to cause a serious adverse event.  
 
• All appropriate measures will be taken to ensure the safety of the subject. Follow the 
subject until the adverse event resolves or until an appropriate endpoint is reached. 
This may imply that follow-up will continue after the subject has left the study.  
 
• A treatment of an AE will depend on the severity of the adverse event. The Principal 
Investigator will refer the subject to a suitably licensed eye  care professional for 
immediate treatment if necessary. 
 

Protocol 21-003:  2-Hour Dispensing Evaluation of samfilcon A Lenses with EPG01 Packaging Solution 
Compared to Commercially Available B+L Ultra Lenses 
 
Version 1.0                                                              CONFIDENTIAL                   
August 13, 2021 
 
 
 
 
Page 24 of 49 
 
• Expenses incurred for study-related medical treatment will be paid by Bausch + 
Lomb. Research Clinic Staff will contact Environmental Health and Safety to 
initiate the medical payment claims process. 
 
• If it is determined, based on evaluation of any serious adverse event or serious 
adverse event trending, that the study presents an unreasonable risk, the Research 
Clinic may choose to terminate the study. Refer to the Study Termination 
procedures for additional information and relevant periods for terminating a study.  
 
• All adverse events will be documented in the final study report. Adverse Event 
documentation must be saved in the Trial Master File and in the respective study 
folder in the electronic repository. 
 
6.5 Reporting Device Deficiencies  
• Report to Global Pharmacovigilance and Risk Management (GPRM) and Design 
Quality within 24 Hours. 
• All device deficiencies must be evaluated by the Investigator, and then evaluated by 
GPRM and Design Quality. 
• The Principal Investigator (PI) will record, evaluate, and report via applicable forms 
any complaints/deficiencies or malfunctions experienced with the study devices 
using the Device Deficiency form and when applicable, AE form (if AE has 
occurred). The PI will evaluate the Device Deficiency and record whether an AE 
occurred related to the device deficiency and also determine the potential of the 
device deficiency to cause a serious adverse device effect (SADE). The device 
deficiency form is then sent to GPRM to evaluate as the Sponsor, their independent 
determination if the device deficiency led to or could have led to a SADE.  See ISO 
14155:2020 for resolving any discrepancies between the interpretation by the PI and 
Sponsor on whether the device deficiency could have led to SADE.     
o If there was an Adverse Event that occurred as well as the device deficiency, 
then it should be reported as both an Adverse Event and a Device Deficiency 
(both forms should be completed). 
o If the Device Deficiency is unrelated to an Adverse Event, then just the 
Device Deficiency should be reported on the Device Deficiency form. 
• Additionally, the Device Deficiency form will be sent to Bausch + Lomb Design 
Quality to evaluate whether any updates to Design Records need to be made. 
 
6.6 Emergency Contact Details for Reporting SAE and ADE 
Jeffery Schafer, OD, MS 
Clinical Research Fellow 
Bausch + Lomb Incorporated  
1400 North Goodman Street Rochester, NY 14609 
Tel: 585 338 5664 
Cell:  585 754 4680 (24 Hours) 
Email: Jeffery.Schafer@bausch.com 

Protocol 21-003:  2-Hour Dispensing Evaluation of samfilcon A Lenses with EPG01 Packaging Solution 
Compared to Commercially Available B+L Ultra Lenses 
 
Version 1.0                                                              CONFIDENTIAL                   
August 13, 2021 
 
 
 
 
Page 25 of 49 
 
 
7.0 STATISTICAL METHODS 
 
7.1 Study Endpoints 
Primary Endpoint: 
1. Normalized logMAR Visual Acuity 
 
7.2 Hypotheses 
The null hypothesis is that the difference in mean normalized logMAR VA between the two 
lens types is 0.05 or greater. The alternative hypothesis is that the difference is less than 
0.05. 
 
7.3 Sample Size 
Previous clinical experience with samfilcon A lenses is useful to provide an adequate 
sample size for this investigation. Too few subjects will lead to a decrease in study power. 
The power of a study indicates the chance of making a Type II error (i.e. showing no 
statistical difference even though a difference actually exists). A study power of 100% 
would require an infinite number of subjects. In clinical studies it is generally acceptable to 
use a power as low as 80%, which is a good compromise between number of subjects and 
the risk of not detecting a true difference that exists. The Type I error rate (i.e. chance of 
finding a statistical difference that really doesn’t exist) is typically set at 5% (p=0.05) 
chance. 
 
In a previous study with similar lenses (ROC2-16-032), the standard deviation for logMAR 
VA was 0.069. A sample size of 15 subjects was calculated to have a study power of 80%. 
 
7.4 Randomization 
To minimize or avoid bias, subjects will be assigned randomization numbers as they are 
enrolled according to unique randomization schedules created for the study. The 
randomization schedule will be produced prior to study enrollment. Subjects will be 
receiving each of the study lens types once, in a randomized order. An effort will be made 
to conceal the CTM materials from the subject and the investigator throughout the study. 
Both the study subject and investigator will be masked.  
 
7.5 Study Populations 
Subjects will be included in all summaries under the treatment that they actually 
received. Analyses of safety data will include all dispensed subjects. All other summaries 
will include all eligible, completed subjects. 
7.6 Statistical Analysis 
Continuous data will be summarized using descriptive statistics: n, mean, standard deviation, 
median, minimum and maximum. Categorical data will be presented by the total counts for 
each category and corresponding percentages. The data for each of the ordinal dependent 
measures (i.e., those assigned a clinical grade) will be analyzed using appropriate 
nonparametric techniques. Unless otherwise noted, paired t tests will be used to test for 

Protocol 21-003:  2-Hour Dispensing Evaluation of samfilcon A Lenses with EPG01 Packaging Solution 
Compared to Commercially Available B+L Ultra Lenses 
 
Version 1.0                                                              CONFIDENTIAL                   
August 13, 2021 
 
 
 
 
Page 26 of 49 
 
differences in means for each of the parametric dependent variables. Differences at the p < 
0.05 level will be considered statistically significant.  
 
7.6.1 Pass/Fail Criteria 
There are no pass/fail criteria for the results of the clinical investigation. 
 
7.6.2 Interim Analyses 
No interim analyses are planned. 
 
7.6.3 Exploratory/Sensitivity Analysis 
There are no planned exploratory or sensitivity analyses for this study. 
 
7.6.4 Deviations 
Any deviations from the original statistical analysis plan will be summarized in the Clinical 
Study Report.  
8.0 DATA QUALITY ASSURANCE 
Prior to the start of the study, member(s) of the Research Clinic and Investigators will 
review the protocol, e-CRFs, regulatory obligations, and other material or equipment 
relevant to the conduct of the study. 
 
During the study, if it is determined that an Investigator is not compliant with the protocol 
and/or applicable regulatory requirements, action will be taken to secure compliance. In 
addition, the Investigator’s participation in the study may be terminated if appropriate, or if 
the Investigator remains non-compliant. 
 
8.1 Study Monitoring 
The monitoring plan for this study includes Informed Consent and Data Verification.  
 
8.1.1 Monitoring Subject Risk  
The risks involved with contact lens wear in this study will be minimized because the 
subjects will be examined frequently and at specified intervals.  The risks are further 
minimized by the study eligibility criteria.  The subject population will be restricted to 
persons who are 18 years of age or older and have full legal capacity to volunteer; no 
restrictions are made as to gender. 
  
8.1.2 Monitoring Informed Consent Process  
Informed consent forms are verified for all subjects enrolled in each study.  Subject and 
witness signature and date are visually verified by the CRT and then confirmed in the EDC 
System at the time of enrollment. Informed Consent Form signatures are also verified 
during study reconciliation by CRT. The signed informed consent forms are kept in the 
study folder. 
  
8.1.3 Data Verification 
Edit checks are built into the EDC System to minimize the chance of error.  For example, 

Protocol 21-003:  2-Hour Dispensing Evaluation of samfilcon A Lenses with EPG01 Packaging Solution 
Compared to Commercially Available B+L Ultra Lenses 
 
Version 1.0                                                              CONFIDENTIAL                   
August 13, 2021 
 
 
 
 
Page 27 of 49 
 
the EDC System does not allow the same study material to be dispensed more than once. 
The expected ranges of values are specified in the EDC System. If data falls outside of the 
expected range, the CRT will be prompted to answer a query. 
  
Data is collected by the CRT or Delegate using either Direct Entry with Verification or 
Double Data Entry.   
 
8.1.3.1 Direct Entry with Verification  
Direct Entry with Verification is the preferred method for entering study data. Data is 
collected by the CRT or Delegate and entered directly into the EDC System.  A second 
person, typically the Primary Investigator (or Delegate), will visually verify the data as it is 
entered, except masked information when applicable. 
• In the event that the EDC System is unavailable, a paper CRF will be used to collect 
study data for later entry into the EDC System. After each page of the CRF is 
entered into the EDC System, the CRT or Delegate will initial the CRF to indicate 
the data has been entered into the EDC System and visually verified. 
• Randomization Verification is required at the conclusion of each study prior to data 
distribution. The CRT or Delegate will verify each dispensed article against the 
study randomization and Clinical Trial Material (CTM) label, if applicable. After 
Randomization Verification of dispensed article, the CRT or Delegate will mark the 
Verification checkbox in the EDC System to acknowledge completion of dispensed 
article verification. 
• If discrepancies arise during the verification of a paper source, the CRT or Delegate 
assesses the discrepancy and obtains additional information to determine if the 
correct entry was made or corrects paper source as appropriate. The CRT or 
Delegate may consult the Primary Investigator if necessary. 
• The data is extracted from the EDC System and checked for accuracy by comparing 
the extracted data to the data originally recorded in the EDC System. The data 
extract is checked to confirm the lens reformat codes match the lens key. 
Calculations performed by the EDC System are checked for accuracy. 
• Database Randomization Verification is performed, if applicable, prior to data 
distribution. 
  
8.1.3.2 Double Entry of Data  
If data is not entered directly in the EDC system, the data will be double entered (entered 
twice) and the two sets of data will be compared to each other and then checked for 
discrepancies.  
  
When a paper source (i.e. subject questionnaire) is used to collect study data, this method 
may be used.  For example, a subject questionnaire will be entered into two different 
spreadsheets.  The two spreadsheets are then compared to each other. 
• If discrepancies arise during the verification of a paper source, the CRT or Delegate 
assesses the discrepancy and obtains additional information to determine if the 
correct entry was made or corrects the paper source as appropriate. The CRT or 
Delegate may consult the Primary Investigator if necessary. 

Protocol 21-003:  2-Hour Dispensing Evaluation of samfilcon A Lenses with EPG01 Packaging Solution 
Compared to Commercially Available B+L Ultra Lenses 
 
Version 1.0                                                              CONFIDENTIAL                   
August 13, 2021 
 
 
 
 
Page 28 of 49 
 
• After the study data from the paper source is entered, each CRT or Delegate entering 
the data will initial the paper source  to indicate that the data has been entered into 
the EDC System visually verified, and dispensed articles verified against study 
randomization, prior to data distribution. 
• The data is extracted from the EDC System and checked for data accuracy and 
necessary calculations are performed. 
  
8.1.3.3 The Data Management Summary (DMS)  
A Data Management Summary is created after all data has been verified. 
  
8.1.4 Annual Research Clinic Monitoring Plan 
On a yearly basis, unless otherwise specified, a qualified internal or external Clinical 
Monitor will audit a random sample of approximately 10% or a minimum of 5 of the 
IRB/IEC approved and conducted trials from the previous year. The selected trials should 
be representative of the Primary Investigators and Clinical Research Technicians that have 
worked on trials that year and represent typical studies conducted that year.   
 
The Monitor will ensure that subject protection/privacy was adhered to, all eligibility 
criteria were met and that all study procedures and the reporting of adverse events were 
performed according to the IRB/IEC approved protocols and that Clinical Trial Material 
was appropriately managed and reconciled. 
8.1.4.1 Monitoring Procedure 
1. Review 10% of the subjects for the trials selected. When reviewing the 10% of 
selected subjects, if greater than 25% discrepancies are found on study and safety 
endpoints then data from all subjects for the selected trials will be reviewed. 
Informed Consent Forms are checked for all subjects enrolled in each study. If 
applicable, Adverse Events (AEs) and/or medical treatment events are reviewed for 
all subjects enrolled in each study. 
a. Verify 100% of the CRF/eCRF fields for all subjects to the available source 
documentation for primary variables, visual acuity and slit lamp exam. 
b. Review source documents (if applicable) for AEs and/or medical treatment 
events. If any safety events have occurred, review safety event 
documentation to ensure that all events have been reported to Sponsor and/or 
IRB/IEC and that supporting documentation is consistent (i.e., source, 
Adverse Event (AE) form, medical treatments, etc.). If an unreported safety 
event is discovered, notify the Principal Investigator. 
c. Review all test product/IP randomization assignment, dispensing and the 
Clinical Trial Material Tracking Document (RC-200-FORM-009) entries to 
ensure proper randomization, dispensing and return of IP and accuracy of the 
data, if applicable. 
2. RC Regulatory Binder and IRB/IEC approval documentation will be reviewed. 
3. Relevant documentation will be completed.  
 
8.1.4.2 Site Performance Evaluation & Monitoring Report  
The Monitor should complete the appropriate Site Performance Evaluation & Monitoring 

Protocol 21-003:  2-Hour Dispensing Evaluation of samfilcon A Lenses with EPG01 Packaging Solution 
Compared to Commercially Available B+L Ultra Lenses 
 
Version 1.0                                                              CONFIDENTIAL                   
August 13, 2021 
 
 
 
 
Page 29 of 49 
 
Report within ten business days of the site visit and forward an electronic copy of the 
completed draft report to the Research Clinic Director (RCD) or Delegate for review. 
 
8.2 Auditing Procedures 
Audits of clinical research activities in accordance with Bausch + Lomb’s internal Standard 
Operating Procedures to evaluate compliance with the principles of GCP may take place. A 
regulatory authority may also wish to conduct an inspection (during the study or after its 
completion).  
 
8.3 Source Documentation 
Source documentation consists of original subject documents, as well as data and records 
with information relevant to the subject and his/her participation in the study.  The data 
collected in the CRF/e-CRFs at all the visits will be available to the Investigator after the 
conclusion of the trial.   
Examples of source documents include: hospital records, clinical and office charts, 
laboratory notes, memoranda, signed ICF, evaluation checklists, recorded data from 
automated instruments, copies or transcriptions certified after verification as being accurate 
copies, and information initially recorded in an electronic format.  
 
Subject completed forms are also considered to be source data, if applicable to the study. 
The Investigator or designee should review subject completed forms for completeness and 
accuracy. 
 
8.4 Maintaining Subject Privacy 
Subjects’ participation in this study and their study records (including photographs and 
video/audiotapes) will be held in a way that will protect their privacy, except when ordered 
by law.  It may be necessary for other people to review their records for study reasons.  These 
people may include:   
  
• 
The Investigator  
• The United States Food and Drug Administration (FDA)  
• Other state or federal regulatory agencies  
• The Institutional Review Board (IRB)  
• Contracted monitors or auditors  
• Bausch + Lomb personnel associated with the study analysis and reporting  
  
If this occurs, their identity will be protected as legally required.  If results of the study are 
published, subjects will not be identified by name.   
  
The Institutional Review Board (IRB) and accrediting agencies may inspect and copy 
subjects’ records, which may have the subjects’ name on them.  Therefore, total 
confidentiality cannot be guaranteed.  If the study results are presented at meetings or 
printed in publications, subject names will not be used.  
 
Data pertaining to subjects is only available to Bausch + Lomb personnel. Physical data 

Protocol 21-003:  2-Hour Dispensing Evaluation of samfilcon A Lenses with EPG01 Packaging Solution 
Compared to Commercially Available B+L Ultra Lenses 
 
Version 1.0                                                              CONFIDENTIAL                   
August 13, 2021 
 
 
 
 
Page 30 of 49 
 
remains locked and electronic data is password protected. When subjects receive an 
electronic recruitment invitation, all other potential subjects are blind carbon copied on the 
invitation to ensure patient privacy.  
 
Clinical trial data is input into a secure, electronic data capture system in which only 
relevant study personnel have access. Subject data recorded on CRF/e-CRFs during the 
study will be documented in a coded fashion. The subject will only be identified by the 
subject number. Confidentiality of subject records must be maintained to ensure subject 
privacy.  
 
8.5 Locking the Database 
After the study is complete, the data is approved by the Principal Investigator via electronic 
signature. The database is then locked. Any change to the data after database lock will 
require approval from the EDC Programmer and is documented via electronic audit trail. 
 
8.6 Retention of Documents 
Bausch + Lomb must retain essential documents indefinitely after the completion of the 
study. The Research Clinic keeps physical study related documents physically on-site for a 
minimum of 3 years. After 3 years, the documents may be securely stored in an off- site 
location. Additionally, data is securely stored electronically.  
 
Essential documents include but are not limited to the following: 
• 
IRB approvals for the study protocol, all amendments, ICF(s), and advertisements 
• 
IRB correspondence and reports (e.g., AE reports, protocol deviations, and safety 
updates) 
• 
regulatory documents  
• 
subject’s signed ICF 
• 
accountability records for the test article(s) 
• 
any other documents relevant to the conduct of the study  
 
8.7 Clinical Quality Assurance 
Prior to being evaluated clinically, investigational devices such as contact lenses or 
solutions are analyzed and approved for release by the project manager and design quality at 
Bausch and Lomb, Rochester, NY.   Documentation of pre-clinical testing can be found on 
the study’s clinical scorecard for the relevant products.  
 
8.8 Institutional Review Board 
The Investigator should ensure their participation in the study, in addition to the protocol, 
subject recruitment materials and the ICF to be used in this study are approved by the 
reviewing IRB prior to entering any subjects in the study. In addition, the Investigator must 
ensure that the reviewing IRB has provided approval for any protocol amendments prior to 
implementation. If the amendment necessitates a revision to the ICF, the Investigator should 
ensure the revised form is also submitted to and approved by the IRB and implemented as 
directed. 
 

Protocol 21-003:  2-Hour Dispensing Evaluation of samfilcon A Lenses with EPG01 Packaging Solution 
Compared to Commercially Available B+L Ultra Lenses 
 
Version 1.0                                                              CONFIDENTIAL                   
August 13, 2021 
 
 
 
 
Page 31 of 49 
 
8.9 Statements of Compliance 
This study is being conducted in accordance with 21CFR Parts 11, 50, 54, 56 and 812; 42 
USC 282(j); ISO 14155:2020 Clinical investigation of medical devices for human subjects - 
Good Clinical Practice; International Council for Harmonization (ICH) Good Clinical 
Practice (GCP) - Declaration of Helsinki and applicable local regulations.  
 
This clinical investigation will demonstrate compliance with this document. 
The clinical investigation shall not begin until the required approval from the IRB has been 
obtained. Any additional requirements imposed by the IRB shall be followed. 
No insurance will be provided to the subjects.  
Bausch + Lomb is financing this clinical investigation. The investigators are paid 
employees of Bausch + Lomb.  
 
8.10 Informed Consent Process 
All subjects will be given a copy of the Informed Consent Form (ICF) to read prior to 
enrollment.  Subjects will have an opportunity to ask questions prior to enrollment and 
throughout the study. The ICF also contains information on payment for participating in the 
study.  All subjects will need to sign the ICF prior to participation in the study. The person 
obtaining informed consent will also sign and date the form.  The subject’s signed informed 
consent must be obtained before conducting any study related procedures. The original will 
be retained by the investigative site. A copy of the signed ICF will be given to the subject. If 
modifications are made to the ICF, the new version must be approved by the IRB. The new 
version of revised ICF(s) must be reviewed and signed by all active (if required by the IRB) 
and new subjects at the first opportunity after approval by the IRB. 
 
For this study, subjects will have the capacity to provide written voluntary informed 
consent. Emergency treatment is not applicable. No minors or those who cannot speak 
English or read or write will be recruited for this study. 
8.10.1 Vulnerable Population 
The subject population recruited for this clinical investigation could be considered 
vulnerable due to subjects being employees of Bausch + Lomb.   
 
Employees volunteer to participate in the Research Clinic.  Based on the individual study 
inclusion and exclusion criteria, employees are notified of potential eligibility and asked to 
respond if they are interested in participation. Participation is completely voluntary.  
 
All subjects will be given a copy of the Informed Consent Form (ICF) to read and will also 
have an opportunity to ask questions to the Investigator or designee prior to enrollment. All 
subjects will need to sign the Informed Consent Form prior to participation in the study.  
 
The Informed Consent form addresses voluntary participation and the decision to participate 
or not will not affect your performance evaluation, possible promotion, or pay.  
 

Protocol 21-003:  2-Hour Dispensing Evaluation of samfilcon A Lenses with EPG01 Packaging Solution 
Compared to Commercially Available B+L Ultra Lenses 
 
Version 1.0                                                              CONFIDENTIAL                   
August 13, 2021 
 
 
 
 
Page 32 of 49 
 
After the study is complete, there is no planned/routine medical follow-up care. 
 
8.11 Publication of Results 
All study data generated as a result of this study will be regarded as confidential, until 
appropriate analysis and review by Bausch + Lomb or its designee and the Investigator(s) 
are completed. The results of the study may be published or presented by Bausch + Lomb.  
 
9.0 BIBLIOGRAPHY  
There are no references for this study.  
 
 
 

Protocol 21-003:  2-Hour Dispensing Evaluation of samfilcon A Lenses with EPG01 Packaging Solution 
Compared to Commercially Available B+L Ultra Lenses 
 
Version 1.0                                                              CONFIDENTIAL                   
August 13, 2021 
 
 
 
 
Page 33 of 49 
 
APPENDIX A: METHODS OF CLINICAL EVALUATION 
Maintenance and calibration of the equipment relevant to study assessments must be 
appropriately performed and documented by the investigative site, where applicable. Any 
changes to the procedures described in this appendix will be provided under separate cover. 
 
1.0 VISUAL ACUITY 
It is essential that a standard procedure be used to obtain VA measurements. The VA should 
be obtained by a physician, optometrist, or trained technician. 
 
1.1 Procedure for logMAR Visual Acuity 
1. Ensure the appropriate lenses are in place. 
2. Instruct the subject to begin reading the chart at the top line or at a line they are 
confident they will read all 5 letters correctly. 
3. If the subject does not read all 5 letters correctly on the first attempted line instruct 
the subject to read the line above that. If the subject does not read those 5 letters 
correctly, instruct the subject to read the previous line until all 5 letters on a line are 
read correctly. 
4. Once the subject reads all 5 letters correctly on a line instruct them to continue 
reading each line on the chart until three or more of the five letters on a line are 
missed. Guessing should be encouraged.  
5. Record the number of letters the subject reads correctly on each line. 
6. If a subject re-reads a line or letters, their visual acuity score will be calculated based 
on their first response. 
7. The total number of letters read correctly is converted into a logMAR visual acuity 
score. This score is obtained by assigning a value of logMAR = 0.02 to each letter. 
The top row is calibrated (according to the manufacturer’s instructions) to have a 
MAR of 2 min arc, thus if the subject reads the entire line and no more, the visual 
acuity is 0.30 logMAR. Each additional letter read correctly would improve the 
score by 0.02 log units. 
 
 
2.0 SLIT LAMP EXAMINATION 
 
2.1 Grading Contact Lens Centration 
 
2.1.1 Qualitative Lens Centration 
• Compare lens edge overlap of limbus in all visible sectors. 
• If the limbus is an ill-defined band, assess from the center of the band. 
• If the contact lens edge translates with blinking, assess to the average lens edge 
position. 
• Centration assessment applies to primary gaze. 
• If the inferior edge of the contact lens is not visible, gently pull the lower eyelid 
away. 
• Rate and record lens centration on a scale of 0 to 3 based on the following lens 
descriptors: 

Protocol 21-003:  2-Hour Dispensing Evaluation of samfilcon A Lenses with EPG01 Packaging Solution 
Compared to Commercially Available B+L Ultra Lenses 
 
Version 1.0                                                              CONFIDENTIAL                   
August 13, 2021 
 
 
 
 
Page 34 of 49 
 
0) Equal Overlap 360 degrees 
1) Maximum overlap ≤ 2/3 in any sector 
2) Maximum overlap > 2/3 in any sector 
3) Any Corneal Exposure 
 
2.1.2 Quantitative Lens Centration 
• Lens to limbus overlap is the distance from the limbus to the lens edge. 
• Measure the distance in millimeters (mm) in primary gaze using a slit lamp 
eyepiece reticule. 
• Measure the lens-limbus overlap in the temporal, nasal and inferior directions. 
o If the limbus is an ill-defined band, assess from the center of the band. 
o If the contact lens edge translates with blinking, assess to the average lens 
edge position. 
• Centration assessment applies to primary gaze. 
o If the inferior edge of the contact lens is not visible, gently pull the 
lower eyelid away. 
• Rate and record lens centration measurements in millimeters (mm). 
o A positive value indicates corneal coverage. 
o A negative value indicates corneal exposure. 
 
2.2 Grading Contact Lens Movement 
 
2.2.1 Quantitative Lens Movement 
• Vertical lens movement is measured in millimeters (mm) in straight-ahead gaze 
using a slit lamp eyepiece reticule. 
• Lens movement is measured from the most inferior point where the lens 
habitually rests following a blink, to the most superior point of the excursion 
• Movement is measured immediately following a blink. 
• If the inferior edge of the contact lens is not visible, gently pull the lower eyelid 
away. 
• Rate and record measurements in millimeters (mm). 
 
2.3 Grading Corneal Staining (Severity and Extent) 
• Slit lamp illumination- Diffuse illumination with cobalt filter and Wratten filter in 
place, use direct  illumination as needed. 
• Instill Fluorescein. 
• Rate/record corneal staining severity globally  
 
2.3.1 Corneal Staining Severity 
Grading scale is as follows: 
• Grade 0 - None: No fluorescein staining/tracking. 
• Grade 1 - Trace: Minimal superficial staining or stippling, and non-

Protocol 21-003:  2-Hour Dispensing Evaluation of samfilcon A Lenses with EPG01 Packaging Solution 
Compared to Commercially Available B+L Ultra Lenses 
 
Version 1.0                                                              CONFIDENTIAL                   
August 13, 2021 
 
 
 
 
Page 35 of 49 
 
coalescing. Includes superficial foreign body staining/tracking. 
• Grade 2 - Mild: Lightly coalescent or diffuse punctate staining, with no 
stain diffusion into stroma. 
• Grade 3 - Moderate: Significant or densely coalescent punctate staining, including 
slight diffusion of stain into stroma. 
• Grade 4 - Severe: Severe abrasion or erosion with loss of epithelial substance. 
Marked and rapid diffusion of stain into stroma. 
 
2.3.2 Corneal Staining Extent  
Grading scale is as follows: 
• Grade 0 – None 
• Grade 1 – 1 to 25% coverage 
• Grade 2 – 26 to 50% coverage 
• Grade 3 – 51 to 75% coverage 
• Grade 4 – 76 to 100% coverage 
 
2.3.3 Percent Area Corneal Staining 
For each of the five corneal sectors (central, inferior, nasal, superior, and temporal) 
estimate the percentage of area of staining in  each sector. 
 
2.4 Grading Conjunctival Staining (Severity and Extent) 
• Slit lamp illumination- Diffuse illumination with cobalt filter and Wratten filter in 
place. Use direct illumination as needed. 
• Instill Fluorescein. 
• Rate and record observations. 
 
2.4.1 Conjunctival Staining Severity 
Grading scale is as follows.  
• Grade 0: None. No fluorescein staining visible. 
• Grade 1: Trace. Few localized discrete stipples, non-coalescing, in any 
conjunctival area.  Includes superficial foreign body staining/tracking. 
• Grade 2: Mild. Lightly coalescent punctate staining in any conjunctival area. 
Superficial with no stain diffusion into underlying layers. 
• Grade 3: Moderate. Densely coalescent punctate staining in any conjunctival area 
with slight diffusion of stain into underlying layers. 
• Grade 4: Severe. Abrasion or erosion, with noticeable loss of epithelial substance, 
in any conjunctival area with rapid diffusion of stain into underlying layers. 
 
 
 

Protocol 21-003:  2-Hour Dispensing Evaluation of samfilcon A Lenses with EPG01 Packaging Solution 
Compared to Commercially Available B+L Ultra Lenses 
 
Version 1.0                                                              CONFIDENTIAL                   
August 13, 2021 
 
 
 
 
Page 36 of 49 
 
2.4.2 Conjunctival Staining Extent 
• Grade conjunctival staining extent by counting the number of clock hours of 
staining that are present around the circumference of the limbus. 
• The extent may not be continuous, as such add up the total number of clock hours 
observed to determine the extent grade. 
 
2.6 Grading Limbal and Bulbar Injection (Redness) 
• Slit lamp illumination- White light, medium intensity. Use direct and indirect 
illumination as needed. 
• Rate and record observations. 
 
2.6.1 Limbal Injection (Redness) 
Grading scale is as follows: 
• Grade 0 – None. No hyperemia present. Normal appearance of limbal vessels. 
• Grade 1 – Trace. Very slight hyperemia of limbal vessels. 
• Grade 2 – Mild. Mild hyperemia of limbal vessels.  
• Grade 3- Moderate. Marked hyperemia of limbal vessels in any quadrant.  
• Grade 4 – Severe. Very marked hyperemia of limbal vessels in any quadrant. 
 
2.6.2 Bulbar Injection (Redness) 
Grading scale is as follows: 
• Grade 0 – None. No hyperemia present. Normal appearance of bulbar conjunctival 
vessels for that subject. 
• Grade 1 – Trace. Very slight hyperemia of bulbar conjunctival vessels. 
•  Grade 2 – Mild. Mild hyperemia of bulbar conjunctival vessels. 
• Grade 3 – Moderate. Marked hyperemia of bulbar conjunctival vessels in any 
quadrant. 
• Grade 4 – Severe. Very marked hyperemia of bulbar conjunctival vessels in any 
quadrant. 
 
2.7 Evaluation of Lens Surface Deposits 
Examine the lens for presence of deposits immediately after a blink. Estimate the total extent 
of all deposits based on the scales below. Rate and record lens deposits findings. 
 
2.7.1 Grading Deposit Extent 
• Grade 0 – No front surface deposits. 
• Grade 1 – Presence of 5 or less small (<0.1mm) individual deposits. 
• Grade 2 – Presence of 5 to 10 small, individual deposits (0.1mm to 0.5mm in 
diameter) or individual deposit larger than 0.5mm in diameter (all covering less 
than 25% of the lens surface). 
• Grade 3- Deposits covering 25-50% of the lens surface.  
• Grade 4 –Deposits covering >50% of the lens surface. 
 

Protocol 21-003:  2-Hour Dispensing Evaluation of samfilcon A Lenses with EPG01 Packaging Solution 
Compared to Commercially Available B+L Ultra Lenses 
 
Version 1.0                                                              CONFIDENTIAL                   
August 13, 2021 
 
 
 
 
Page 37 of 49 
 
2.8 Evaluation of Lens Surface Wettability 
On-eye lens wettability is determined by observations of the spread of tears over the lens 
after blinking. Examine the pre-lens tear film immediately after a blink. Rate and record 
lens wettability findings. 
 
2.8.1 Characterize the on-eye lens wettability observed using the following scale: 
• Grade 0 – Perfectly wettable lens surface (i.e. equivalent to normal healthy tear 
film). 
• Grade 1 – Wets uniformly but shortly after blinking a small area of transient non-
wetting appears. 
• Grade 2 – One stable dry (non-wetting) area after blinking. 
• Grade 3 – More than one non-wetting patch immediately after blinking.  
• Grade 4 – Hydrophobic lens surface. 
 
2.8.2 Estimate the total extent of non-wetting areas based on the following 0-4 scale: 
• Grade 0 – Absence of non-wetting areas. 
• Grade 1– Non-wetting areas covering 1 clock hour or less (i.e. ≤8% or 1/12) of the 
surface area. 
• Grade 2– Non-wetting areas covering 2 clock hours or less (i.e. ≤17% or 2/12) of 
the surface area. 
• Grade 3– Non-wetting areas covering 3 clock hours or less (i.e. ≤25% or 3/12) of 
the surface area. 
• Grade 4– Non-wetting areas covering more than 3 clock hours (i.e. >25%) of the 
surface area. 
 
 

Protocol 21-003:  2-Hour Dispensing Evaluation of samfilcon A Lenses with EPG01 Packaging Solution 
Compared to Commercially Available B+L Ultra Lenses 
 
Version 1.0                                                              CONFIDENTIAL                   
August 13, 2021 
 
 
 
 
Page 38 of 49 
 
3.0 SUBJECTIVE ASSESSMENT RATING SCALES 
Subjective Assessment Rating Scales used for collecting subjective data for clinical studies.  
3.1 Subjective Assessment Rating Scale Procedure 
Subjects will be asked to rate subjective judgements associated with the use of contact lenses, 
solutions or drops utilizing Subjective Assessment Rating Scales.  
Subjects will be provided with a specific Rating Scale and the optometrist or the technician 
will ask them to provide their rating for the attribute the Rating Scale is referencing.  
Each Rating Scale ranges from 0 (very unfavorable) to 100 (very favorable) with descriptors 
at increments of 20 for the subject to reference. 
 
 
 

Protocol 21-003:  2-Hour Dispensing Evaluation of samfilcon A Lenses with EPG01 Packaging Solution 
Compared to Commercially Available B+L Ultra Lenses 
 
Version 1.0                                                              CONFIDENTIAL                   
August 13, 2021 
 
 
 
 
Page 39 of 49 
 
 
 

Protocol 21-003:  2-Hour Dispensing Evaluation of samfilcon A Lenses with EPG01 Packaging Solution 
Compared to Commercially Available B+L Ultra Lenses 
 
Version 1.0                                                              CONFIDENTIAL                   
August 13, 2021 
 
 
 
 
Page 40 of 49 
 
 
 
 
 

Protocol 21-003:  2-Hour Dispensing Evaluation of samfilcon A Lenses with EPG01 Packaging Solution 
Compared to Commercially Available B+L Ultra Lenses 
 
Version 1.0                                                              CONFIDENTIAL                   
August 13, 2021 
 
 
 
 
Page 41 of 49 
 

Protocol 21-003:  2-Hour Dispensing Evaluation of samfilcon A Lenses with EPG01 Packaging Solution Compared 
to Commercially Available B+L Ultra Lenses 
 
Version 1.0                                                              CONFIDENTIAL                   
August 13, 2021 
 
 
 
 
Page 42 of 49 
 
APPENDIX B: SUBJECT INSTRUCTIONS FOR USE 
 
CAUTION: Investigational device. Limited by Federal (U.S.A.) Law to investigational use only. 
 
INTRODUCTION 
 
As a participant in this study, you will wear a pair of study contact lenses for approximately 2 
hours. You will be randomly assigned to wear the test lens in one eye and the control lens in the 
other eye. 
 
Do not discuss or describe the study or the study materials with anyone except the person who 
gave you the study materials at the Screening/Dispensing Visit. You should not show the study 
blister packs and foils to the Investigator unless instructed to do so. 
 
STUDY PRODUCT INFORMATION 
 
 
Study Contact Lenses- You will be provided with one pair of contact lenses to wear for 
approximately two hours. 
 
Study Solution-There is no contact lens care solution in this study. 
 
Study Lens Case- There will not be a contact lens storage case provided for this study.  
 
Other study supplies- There will not be any other study supplies or rewetting drops for this 
study. 
 
Do not use any other contact lenses, eye drops or lens care products than those listed above while 
you are wearing the study lenses. 
 
All study materials, used and unused, must be returned.  
 
If you have questions or problems, call: 
Jeffery Schafer, OD, MS 
Bausch + Lomb Incorporated  
1400 North Goodman Street  
Rochester, NY 14609 
Cell: 585 754 4680 (24 Hours) 
 
If you require a medical referral for any eye problems experienced during the study, please refer 
to your informed consent form. 
 
 
 
 
 

Protocol 21-003:  2-Hour Dispensing Evaluation of samfilcon A Lenses with EPG01 Packaging Solution Compared 
to Commercially Available B+L Ultra Lenses 
 
Version 1.0                                                              CONFIDENTIAL                   
August 13, 2021 
 
 
 
 
Page 43 of 49 
 
GENERAL INFORMATION 
 
Please keep all appointments and follow the instructions thoroughly. Remember to wear your 
glasses to your first appointment and bring your glasses to your follow-up appointment. Wear 
your study contact lenses to your follow-up appointment.  
 
These subject instructions apply to both the test and control contact lenses. For all study lenses, it 
is essential to your safety that you read and understand the information and instructions in these 
subject instructions, and have your questions answered before and after you receive contact 
lenses. 
 
Wearing contact lenses is different from wearing eyeglasses. Because they are worn directly on 
your eyes, contact lenses affect the way in which your eyes function. These effects tend to 
increase with the length of time that the lenses remain on your eyes between removals. Although 
the great majority of people successfully wear contact lenses without problems, before you 
decide whether to begin or to continue wearing contact lenses, you should discuss with the study 
investigator the effects of contact lenses on your eyes and the risks associated with wearing 
contact lenses. You also should read the sections in these subject instructions entitled 
"Warnings”, “Adverse Reactions", "Precautions”, and “Wearing Restrictions and Indications". 
Ask the investigator to explain anything that you do not understand, including any additional 
restrictions which may be given to you.  
 
You also need to remember that soft contact lenses, including those covered by these subject 
instructions, are made of a type of plastic that absorbs liquids, vapors, and small particles, and, 
for some people, may collect deposits from your natural eye fluids. Therefore, you should strictly 
follow the instructions contained in these subject instructions entitled “Personal Cleanliness and 
Lens Handling”, and any other instructions given to you by your eye care professional. Any 
failure to follow these instructions and the wearing restrictions will increase the chances of 
contamination, damage to the lenses, or a build-up of deposits on the lenses, which can lead to 
serious, sight-threatening eye infections and injuries. 
 
If problems or symptoms should occur, immediately remove your contact lenses and follow the 
steps described in the sections in these subject instructions entitled "Warnings” and “Adverse 
Reactions". Prompt attention to problems is essential and may require immediate professional 
care. Remember, when wearing soft contact lenses your eyes should look and feel good, and 
your vision should be clear. 
WEARING RESTRICTIONS AND INDICATIONS 
Both the Test and Control contact lenses are indicated for the correction of refractive ametropia 
(myopia and hyperopia) in persons with non-diseased eyes.  
 
WARNINGS 
You should be aware of and fully discuss with the study investigator the following warnings 
pertaining to contact lens wear: 
• 
Problems with contact lenses could result in serious injury to your eye. It is essential that 

Protocol 21-003:  2-Hour Dispensing Evaluation of samfilcon A Lenses with EPG01 Packaging Solution Compared 
to Commercially Available B+L Ultra Lenses 
 
Version 1.0                                                              CONFIDENTIAL                   
August 13, 2021 
 
 
 
 
Page 44 of 49 
 
you follow your eye care professional's direction and all labeling instructions for proper use 
of lenses. Eye problems, including corneal ulcers, can develop rapidly and lead to loss of 
vision. 
• 
Strict compliance with your wearing restrictions, wearing schedule, and follow-up visit 
schedule must be followed. 
• 
Daily disposable wear lenses are not indicated for overnight wear, and you should not 
wear lenses while sleeping.  
• 
Clinical studies have shown that the risk of serious adverse reactions is increased when 
daily wear lenses are worn overnight. 
• 
Studies have shown that contact lens wearers who are smokers have a higher incidence of 
adverse reactions than nonsmokers. 
• 
If you experience eye discomfort, excessive tearing, vision changes, or redness of the eye, 
you should immediately remove lenses and promptly contact your eye care professional. 
 
PRECAUTIONS 
You should be aware of and fully discuss with your eye care professional the following safety 
precautions: 
 
Lens Handling Precautions 
• 
Always wash and rinse hands before handling lenses. Do not get cosmetics, lotions, soaps, 
creams, deodorants, or sprays in the eyes or on the lenses. It is best to put on lenses before 
putting on makeup. Water-base cosmetics are less likely to damage lenses than oil-base 
products. 
• 
Do not touch contact lenses with your fingers or hands if your hands are not free of  foreign 
materials, as microscopic scratches of the lenses may occur, causing distorted vision and/or 
injury to your eye. 
• 
Do not use saliva or anything other than the recommended solutions for lubricating or 
wetting your lenses. 
• 
Be certain that the fingers or hands are free of foreign materials before touching your 
lenses, as microscopic scratches of the lenses may occur, causing distorted vision and/or 
injury to the eye. 
• 
Always handle your lenses carefully and gently and avoid dropping them.  
• 
Always hand the same lens (right or left) to avoid mix-ups.  
• 
Do not touch the lens with your fingernails. 
• 
Carefully follow the handling, insertion, removal, storing and wearing instructions in these 
subject instructions and those prescribed by the study investigator. 
• 
Never use tweezers or other tools to remove your lenses from the lens container unless 
specifically indicated for that use. Pour the lens into the hand. 
 

Protocol 21-003:  2-Hour Dispensing Evaluation of samfilcon A Lenses with EPG01 Packaging Solution Compared 
to Commercially Available B+L Ultra Lenses 
 
Version 1.0                                                              CONFIDENTIAL                   
August 13, 2021 
 
 
 
 
Page 45 of 49 
 
Lens Wearing Precautions 
• 
Never wear your lenses beyond the period recommended by your eye care professional. 
• 
If the lens sticks (stops moving) on the eye, follow the recommended directions on Care for 
a Sticking (Nonmoving) Lens. The lens should move freely on the eye for the continued 
health of the eye. If nonmovement of the lens continues, you should immediately consult 
your eye care professional. 
• 
Avoid, if possible, all harmful or irritating vapors and fumes when wearing lenses. 
• 
If aerosol products are used while wearing lenses, exercise caution and keep eyes closed 
until the spray has settled. 
 
Topics to Discuss with the Eye Care Professional: 
• 
You should not wear contact lenses during water related activities. Exposure to water while 
wearing contact lenses in activities such as swimming, water skiing and hot tubs may 
increase the risk of ocular infection including but not limited to Acanthamoeba keratitis. 
• 
Always contact your eye care professional before using any medicine in the eyes. 
 
Who should know that you are wearing contact lenses? 
• 
You may decide to inform your health care professional about being a contact lens wearer. 
• 
Always inform your employer of being a contact lens wearer. Some jobs may require the 
use of eye protection equipment or may require that you not wear lenses. 
• 
Ask the study investigator whether there are any other wearing restrictions that apply to 
you. Write those restrictions in the spaces provided below and follow them carefully: 
 
 
 
 
 
 
 
 
 
 
 
 
 
ADVERSE REACTIONS (PROBLEMS AND WHAT TO DO) 
You should be aware that the following problems may occur: 
• 
Eyes stinging, burning, itching (irritation), or other eye pain 
• 
Comfort is less than when lens was first placed on eye 
• 
Abnormal feeling of something in the eye (foreign body, scratched area) 
• 
Excessive watering (tearing) of the eyes 
• 
Unusual eye secretions 
• 
Redness of the eyes 
• 
Reduced sharpness of vision (poor visual acuity) 

Protocol 21-003:  2-Hour Dispensing Evaluation of samfilcon A Lenses with EPG01 Packaging Solution Compared 
to Commercially Available B+L Ultra Lenses 
 
Version 1.0                                                              CONFIDENTIAL                   
August 13, 2021 
 
 
 
 
Page 46 of 49 
 
• 
Blurred vision, rainbows, or halos around objects 
• 
Sensitivity to light (photophobia) 
• 
Dry eyes 
 
If you notice any of the above, you should: 
Immediately remove your lenses. 
• 
If the discomfort or problem stops, then look closely at the lens. If the lens is in any way 
damaged, do not put the lens back on your eye. You should remove the lens and place it in 
the provided contact lens case dry. Then insert a new lens on the eye. If the problem 
continues, you should immediately remove the lenses and consult your eye care 
professional. 
 
When any of the above problems occur, a serious condition such as infection, corneal ulcer, 
neovascularization, or iritis may be present. You should keep the lens off your eye and seek 
immediate professional identification of the problem and prompt treatment to avoid serious eye 
damage. 
 
PERSONAL CLEANLINESS, LENS CARE AND LENS HANDLING 
 
Always wash and rise your hands before you handle your contact lenses.  
 
1. Preparing the Lens for Wearing: 
It is essential that you learn and use good hygienic methods in the care and handling of 
your new lenses. Cleanliness is the first and most important aspect of proper contact lens 
care. Your hands should be clean and free of any foreign substances when you handle 
your lenses. The procedures are: 
• 
Always wash your hands thoroughly with a mild soap, rinse completely, and dry 
with a lint-free towel before touching your lenses. 
• 
Avoid the use of soaps containing cold cream, lotion, or oily cosmetics before 
handling your lenses, since these substances may come into contact with the lenses 
and interfere with successful wearing. 
• 
Handle your lenses with your fingertips and be careful to avoid contact with 
fingernails. It is helpful to keep your fingernails short and smooth. 
• 
Start off correctly by getting into the habit of always using proper hygienic 
procedures so that they become automatic. 
 
2. Handling the Lenses: 
• 
Develop the habit of always working with the same lens first to avoid mix-ups. 
• 
Position the lens on your index finger and examine it to be sure that it is moist, 
clean, clear, and free of any nicks or tears. 
• 
Should you accidentally place an inside-out lens on your eye, one of the following 
signs should signal you to remove and replace it correctly. 
a) Less than usual comfort, 
b) The lens may fold on the eye, 

Protocol 21-003:  2-Hour Dispensing Evaluation of samfilcon A Lenses with EPG01 Packaging Solution Compared 
to Commercially Available B+L Ultra Lenses 
 
Version 1.0                                                              CONFIDENTIAL                   
August 13, 2021 
 
 
 
 
Page 47 of 49 
 
c) Excessive lens movement on blink, 
d) Blurred vision. 
 
• 
If the lens folds and sticks together: Place the lens in the palm of your hand and wet 
thoroughly with the recommended rinsing or storing solution. Then GENTLY rub 
the lens between your index finger and palm in a gentle back and forth motion. 
• 
If the lens flattens or drapes across your finger, the lens or your finger may be too 
wet. To correct this, dry your finger by transferring the lens several times from one 
index finger to the other, drying the opposite finger each time. 
 
3. 
Placing the Lens on the Eye 
There are other methods of lens placement. If the following methods are difficult for you, 
your Study Doctor will provide you with an alternate method.  
 
NOTE: If after placement of the lens, your vision is blurred, check for the following:  
The lens is not centered on the eye (see “Centering the Lens,” next in these instructions).  
If the lens is centered, remove the lens (see “Removing the Lens” section) and check for 
the following:  
• cosmetics or oils on the lens (replace the lens)  
• the lens is on the wrong eye  
• the lens is inside-out (it would also not be as comfortable as normal)  
 
If you find that your vision is still blurred after checking the above possibilities, remove 
both lenses and consult your eye care professional.  
 
The One-Hand Placement Technique  
• Place the lens on your index finger. Head up, looking straight ahead, pull down your 
lower eyelid with the middle finger of your placement hand. Look up steadily at a point 
above you. Then place the lens on the lower white part of your eye. Remove your index 
finger and slowly release the lower lid. Look down to position the lens properly. Close 
your eyes for a moment; the lens will center itself on your eye.  
 
The Two-Hand Placement Technique  
• With the lens on your index finger, use the middle finger of the other hand to pull the 
upper lid against the brow. Use the middle finger of your placement hand to pull down 
the lower lid and then place the lens centrally on your eye. While holding this position, 
look downward to position the lens properly. Slowly release your eyelids.  
• If the lens feels uncomfortable, then look in the mirror and gently place a finger on the 
edge of the contact lens and slowly slide the lens away from your nose while looking in 
the opposite direction. Then by blinking, the lens will re-center itself. If the lens still feels 
uncomfortable, follow the steps described in the section of these instructions entitled 
“Adverse Reactions.”  

Protocol 21-003:  2-Hour Dispensing Evaluation of samfilcon A Lenses with EPG01 Packaging Solution Compared 
to Commercially Available B+L Ultra Lenses 
 
Version 1.0                                                              CONFIDENTIAL                   
August 13, 2021 
 
 
 
 
Page 48 of 49 
 
 
4. 
Centering the Lens 
Very rarely, a lens that is on the cornea will be displaced onto the white part of the eye 
during lens wear. This can also occur during placement and removal of the lenses if the 
correct techniques are not performed properly. To center a lens, follow one of the 
procedures below.  
• Hold the upper and lower eyelids open with your fingers. Then while looking in a 
mirror, gently place a finger on the contact lens and gently slide the lens towards the 
center of the eye.  
OR 
• Hold the upper and lower eyelids open with your fingers. Then, while looking in a 
mirror, move your eye towards the lens to place it on the center of the eye.  
 
5. 
Removing the Lens 
• Always remove the same lens first.  
• Wash, rinse, and dry your hands thoroughly.  
• Always be sure that the lens is in the correct position on your eye before you try to 
remove it (a simple check of your vision, closing one eye at a time, will tell you if the 
lens is in the correct position). Look up and slowly pull down your lower eyelid with 
the middle finger of your removal hand and place your index finger on the lower edge 
of lens. Squeeze the lens lightly between the thumb and the index finger and remove 
it. Avoid sticking the edges of the lens together. 
• Remove the other lens by following the same procedure. 

Protocol 21-003:  2-Hour Dispensing Evaluation of samfilcon A Lenses with EPG01 Packaging Solution Compared 
to Commercially Available B+L Ultra Lenses 
 
Version 1.0                                                              CONFIDENTIAL                   
August 13, 2021 
 
 
 
 
Page 49 of 49 
 
• Follow the required lens care procedures described by your eye care professional. 
• NOTE: If this method of removing your lens is difficult for you, your eye care 
professional will provide you with an alternate method. 
 
6. 
Return of Your Study Lenses 
At each visit, you must return all used and unused study materials that were dispensed to you 
during the designated wear periods.  
 
7. 
Emergency: 
If chemicals of any kind (household products, gardening solutions, laboratory chemicals, etc.) 
are splashed into your eyes, you should: FLUSH EYES IMMEDIATELY WITH TAP WATER 
AND THEN REMOVE LENSES PROMPTLY. CONTACT YOUR EYE CARE 
PROFESSIONAL OR VISIT A HOSPITAL EMERGENCY ROOM WITHOUT DELAY.